×
About 2,320 results

ALLMedicine™ Hypophosphatemia Center

Research & Reviews  725 results

Phosphaturic Mesenchymal Tumor Along the Hallux side Inducing a Chronic non-Healing Wou...
https://doi.org/10.1177/15347346221074163
The International Journal of Lower Extremity Wounds; Sun X, Ni P et. al.

Jan 20th, 2022 - Phosphaturic mesenchymal tumor (PMT) is a rare paraneoplastic syndrome characterized by renal phosphate wasting, hypophosphatemia, and bone calcification disorders. Complete surgical resection of the tumor is believed to be the most effective trea...

Hypophosphatemia Is More Common and Is Prognostic of Poorer Outcomes in Severe Alcoholi...
https://doi.org/10.1097/MPA.0000000000001952
Pancreas Wagner J, Hernandez-Blanco Y et. al.

Jan 19th, 2022 - The aim of this study was to determine if hypophosphatemia is more common in patients with severe alcohol-induced acute pancreatitis (AAP). This is a retrospective, single institution, cohort study that analyzed 147 patients admitted to the hospit...

Characterising Pain, QoL, Body Composition, Arterial Stiffness, Muscles and Bones in Adult Persons With XLH and Healthy Controls
https://clinicaltrials.gov/ct2/show/NCT04273490

Jan 18th, 2022 - Hereditary hypophosphatemia (XLH) is a rare, inherited disease. Loss-of-function mutation in PHEX results in excess fibroblast growth factor 23 (FGF23) production and manifests as rickets in children and osteomalacia in adults. FGF23 is a hormone ...

Vitamin D deficiency osteomalacia triggered by long-term social withdrawal and unbalanc...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8757975
Medicine Iwamoto Y, Tatsumi F et. al.

Jan 15th, 2022 - Osteomalacia is caused by an increase in the number of osteoids owing to mineralization failure. There are various causes of osteomalacia, such as hypophosphatemia due to excess production of fibroblast growth factor 23, vitamin D deficiency, insu...

68Ga-DOTATATE Uptake in an Intraosseous Hemangioma, as a Potential Cause of False-Posit...
https://doi.org/10.1097/RLU.0000000000004045
Clinical Nuclear Medicine; Saidi B, Fallahi B et. al.

Jan 14th, 2022 - We present the case of a 32-year-old man with a history of hypophosphatemia and multiple bone fractures, being evaluated at our center for a potential mesenchymal tumor. 68Ga-DOTATATE PET/CT revealed a highly 68Ga-DOTATATE-avid lesion in the ethmo...

see more →

Drugs  91 results see all →

Clinicaltrials.gov  22 results

Characterising Pain, QoL, Body Composition, Arterial Stiffness, Muscles and Bones in Adult Persons With XLH and Healthy Controls
https://clinicaltrials.gov/ct2/show/NCT04273490

Jan 18th, 2022 - Hereditary hypophosphatemia (XLH) is a rare, inherited disease. Loss-of-function mutation in PHEX results in excess fibroblast growth factor 23 (FGF23) production and manifests as rickets in children and osteomalacia in adults. FGF23 is a hormone ...

Registry for Patients With X-Linked Hypophosphatemia
https://clinicaltrials.gov/ct2/show/NCT03193476

Jan 11th, 2022 - Methodology This is an international, multicentre, prospective, non-interventional, observational Registry of patients with X-Linked hypophosphatemia (XLH). The objectives of this XLH Registry is to collect natural history data of XLH to character...

Examining the Effect of Burosumab on Muscle Function
https://clinicaltrials.gov/ct2/show/NCT04146935

Dec 17th, 2021 - X-linked hypophosphatemia is a skeletal dysplasia. The mineralized tissue complications of XLH have been the focus of investigative studies seeking to understand its pathogenesis, as well as studies directed at new therapies. However, in addition ...

Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of Burosumab in Patients Less Than 1 Year of Age
https://clinicaltrials.gov/ct2/show/NCT04188964

Aug 9th, 2021 - BUR-CL207 is a multicenter, open-label, non-randomized Phase 1/2 study in pediatric patients with XLH initiating treatment with burosumab at <12 months of age. The study includes a total treatment period of up to 48 weeks across 3 cohorts. Subject...

Prevention of Spontaneous Dental Abscesses in Children With X-linked Hypophosphatemia : a RCT
https://clinicaltrials.gov/ct2/show/NCT04872907

May 5th, 2021 - X-linked hypophosphatemia (XLH) is a vitamin D-resistant familial rickets resulting from a mutation of the PHEX gene. One of the major clinical disorders is dental pulp necrosis, which results in "spontaneous" dental abscesses not related to cario...

see more →

News  90 results

X-Linked Hypophosphatemia Exacts Early, High Toll on Musculoskeletal System
https://www.medscape.com/viewarticle/962020

Nov 2nd, 2021 - NEW YORK (Reuters Health) - Adults with X-linked hypophosphatemia (XLH) have high rates of musculoskeletal problems that start as early as age 20 years and gradually accumulate over the years, a new analysis confirms. XLH is a rare inherited disor...

Infigratinib Shows Promising Early Activity in FGFR2-Altered Cholangiocarcinoma
https://www.onclive.com/view/infigratinib-shows-promising-early-activity-in-fgfr2-altered-cholangiocarcinoma

Nov 1st, 2021 - The FGFR inhibitor infigratinib (Truseltiq) demonstrated promising clinical activity and a manageable safety profile in previously treated patients with locally advanced or metastatic cholangiocarcinoma whose tumors harbor FGFR2 gene fusions or re...

Failed Studies Provide Clues in Renal Cell Carcinoma
https://www.onclive.com/view/failed-studies-provide-clues-in-renal-cell-carcinoma

Oct 6th, 2021 - Brian Rini, MD The mTOR inhibitor temsirolimus has limited utility in combination with frontline bevacizumab and as a second-line single agent for patients with metastatic renal cell carcinoma (mRCC), according to two recently published articles ...

Cilta-Cel Continues to Yield Deep, Durable Response in Relapsed/Refractory Myeloma
https://www.onclive.com/view/cilta-cel-continues-to-yield-deep-durable-response-in-relapsed-refractory-myeloma

Sep 10th, 2021 - A single dose of ciltacabtagene autoleucel (cilta-cel) continued to elicit early, deep, and durable responses and showcase a manageable safety profile in heavily pretreated patients with multiple myeloma, according to updated data from the phase 1...

HR-positive breast cancer: Entinostat fails phase 3 trial
https://www.mdedge.com/hematology-oncology/article/245091/breast-cancer/hr-positive-breast-cancer-entinostat-fails-phase-3

Aug 31st, 2021 - Key clinical point: Adding entinostat to e xemestane does not improve survival in aromatase inhibitor (AI)-resistant advanced hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer. Major finding: Th.

see more →